trial

Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812

NCTId NCT00411866
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 36 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2007-10-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
36 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-10-13
Primary completion
2007-10-10
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
SB773812Ketoconazole

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

1 total
Dundee, United Kingdom

Facts & assertions

4 sourced
Enrollment
36
Phase
PHASE1
Primary Completion Date
2007-10-10
Status
COMPLETED
relationships
The graph out of here
drug
SB773812
drug
Ketoconazole
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication